Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis

Keyphrases

• Canadian children 8%
• Children at Risk 100%
• Chronic Lung Disease of Prematurity 16%
• Chronological Age 8%
• Clinical Setting 8%
• Confidence Interval 33%
• Congenital Heart Disease 16%
• Gestational Age 16%
• High Risk 8%
• High-risk Infants 100%
• Hospitalization 8%
• Human Metapneumovirus (hMPV) 8%
• Human Respiratory Tract 8%
• Intensive Care Unit Admission 16%
• Inverse Propensity Score 16%
• Lower Respiratory Tract Infection 16%
• Molecular Detection 8%
• Multiple Logistic Regression Model 8%
• Nasopharyngeal Aspirate 8%
• Palivizumab 100%
• Premature Birth 8%
• Propensity Score 100%
• Randomized Trial 8%
• Regression Analysis 100%
• Respiratory Syncytial Virus 33%
• Respiratory Syncytial Virus Hospitalization 8%
• Test-negative Design 16%
• US children 8%
• Weight Adjustment 8%
• Weighted Regression 100%

Medicine and Dentistry

• Case-Control Study 8%
• Chronic Lung Disease 16%
• Design Controls 8%
• Gestational Age 16%
• High Risk Infant 100%
• Human Metapneumovirus 8%
• Human Respiratory Syncytial Virus 41%
• Intensive Care Unit 16%
• Lower Respiratory Tract Infection 16%
• Multivariate Logistic Regression Analysis 8%
• Nasopharyngeal Aspiration 8%
• Palivizumab 100%
• Persistent Truncus Arteriosus 16%
• Prematurity 25%